This is a working overview of research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-20. Anything still debated is marked as such rather than presented as settled.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
CYP2D6 is the primary enzyme involved in the metabolism of vortioxetine, but others including CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP3A4/5 are also involved. It is also metabolized by alcohol dehydrogenase, aldehyde dehydrogenase, and aldehyde oxidase. Six metabolites of vortioxetine have been identified. The major metabolite of vortioxetine (Lu AA34443) is inactive and its minor active metabolite (Lu AA39835) is not thought to cross the blood–brain barrier. The remaining metabolites are glucuronide conjugates. Hence, vortioxetine itself is thought to be primarily responsible for its pharmacological activity. The estimated total clearance of vortioxetine ranges from 30 to 41 L/h. The elimination half-life of vortioxetine is 66 hours, with a range of 59 to 69 hours after single or multiple doses. Elimination of vortioxetine is almost entirely via the liver (99%) rather than the kidneys (<1%). Approximately 85% of vortioxetine was recovered in a single-dose excretion study after 15 days, with 59% in urine and 26% in feces.
=== Natural hypoallergenic milk for infants with cows' milk protein allergy === Pasteurized donkey milk is used as a natural hypoallergenic milk because it is tolerated by about 90% of infants with food allergies, e.g., cows' milk protein allergy (CMPA), a common food allergy in childhood with a prevalence of approximately 3% during the first 3 years of life. However, an infant's tolerance to donkey milk must be evaluated under medical supervision, and after carrying out specific allergy tests. Natural hypoallergenic formula is preferred over those of soy or produced from protein hydrolysates because it has a pleasant taste and may not cause allergies in people who also have allergic reactions to soy proteins or protein hydrolysates.
Wong was also the first woman to be executed for murder in Singapore since its independence. 1975: Andrew Chou Hock Guan, David Chou Hock Heng, Peter Lim Swee Guan, Alex Yau Hean Thye, Stephen Francis, Richard James, and Konesekaram Nagalingam, who were hanged on 28 February 1975 for the Gold Bars triple murders. 1975: Lim Kim Huat and Neoh Bean Chye, the two Malaysian gunmen found guilty of shooting and killing wine shop proprietor Chew Liew Tea and hanged on 27 June 1975. 1980: Quek Kee Siong, a labourer who was found guilty of the rape and murder of ten-year-old Cheng Geok Ha and sentenced to death in March 1979. He lost his appeal in November 1980, and later hanged. 1982: Kalidass Sinnathamby Narayanasamy, a lance corporal of the Singapore Armed Forces who molested and killed his seven-year-old niece. He was sentenced to hang for murder on 27 March 1980 and lost his appeal in May 1982, and sometime afterwards, he was executed. 1982: Haw Tua Tau, a hawker who was found guilty of murdering Phoon Ah Leong and Hu Yuen Keng back in 1976. After losing his appeals, Haw was hanged sometime in 1982. 1983: Vadivelu Kathikesan, a Singaporean charged with the murders of two men between June and October 1979. Vadivelu was sentenced to hang in March 1982 for the October 1979 murder of cigarette stall owner Mohamed Dawood Abdul Jaffar, and he was hanged on an unknown date after the loss of his appeal in January 1983. His other charge of killing Abdul Rahiman Adnan in June 1979 was withdrawn after his conviction for the Mohamed Dawood murder.
Sources: en.wikipedia.org
The motto of Schleswig-Holstein is "Up ewich ungedeelt" (Middle Low German: "Forever undivided", modern High German: "Auf ewig ungeteilt"). It goes back to the Treaty of Ribe (Danish: Ribe Håndfæstning German: Handfeste von Ripen) in 1460. Ripen (Ribe) is a historical small town in Northern Schleswig, nowadays Denmark. The anthem from 1844 is called "Wanke nicht, mein Vaterland" ("Don't falter, my fatherland"), but it is usually referred to with its first line "Schleswig-Holstein meerumschlungen" (i.e., "Schleswig-Holstein embraced by the seas") or "Schleswig-Holstein-Lied" (Schleswig-Holstein song). The old city of Lübeck is a UNESCO World Heritage Site.
== Demographics == According to the 2021 Canadian census, 2023 representation order Racial groups: 83.2% White, 10.4% Black, 2.5% Arab, 2.2% Latin American, 1.4% Indigenous Languages: 87.3% French, 4.2% English, 2.3% Creole, 2.3% Spanish, 1.4% Arabic, 1.0% Italian Religions: 68.9% Christian (57.9% Catholic, 11.0% Other), 4.2% Muslim, 26.1% None Median income: $45,600 (2020) Average income: $53,750 (2020)
The United States Department of Defense asks the US defense sector to accelerate the manufacturing and delivery of armaments, including ammunition that is in short supply because of the 2026 Iran war. Royce White becomes the second former NBA player, after Enes Kanter Freedom, to declare that they are eligible for the 2027 WNBA draft. August 9 – 2026 cyclosporiasis outbreak, salmonellosis in the United States: Taylor Farms extends its recalls to products containing jalapeños after they were linked to the ongoing salmonellosis outbreak in the United States. Taylor Farms currently has a recall for iceberg lettuce linked to cyclosporiasis. August 10 Staff secretary Will Scharf is named as White House counsel by Trump. Trump states that he instructed US negotiators to demand reparations from the Iranian regime for Americans it has killed and seriously injured in conflicts, as well as the families of protesters who were slain in Iran, falsely claiming that it was involved in the attack on the USS Cole. Trump also states that the regime should be held accountable for damages and deaths inflicted on Lebanese, Palestinian, Syrian, and Yemeni civilians. August 11 Democratic senators Richard Blumenthal and Adam Schiff investigate the alleged coordination between ICE and the Iranian regime to deport detainees. US rights organizations sue Trump over sanctions against the ICC. August 12 A Pentagon assessment finds that US strikes targeting the Houthis killed 153 civilians in Yemen over the past year.
Most modern nuclear weapons utilize 238U as a "tamper" material (see nuclear weapon design). A tamper which surrounds a fissile core works to reflect neutrons and to add inertia to the compression of the 239Pu charge. As such, it increases the efficiency of the weapon and reduces the critical mass required. In the case of a thermonuclear weapon, 238U can be used to encase the fusion fuel, the high flux of very energetic neutrons from the resulting fusion reaction causes 238U nuclei to split and adds more energy to the "yield" of the weapon. Such weapons are referred to as fission-fusion-fission weapons after the order in which each reaction takes place. An example of such a weapon is Castle Bravo. The larger portion of the total explosive yield in this design comes from the final fission stage fueled by 238U, producing enormous amounts of radioactive fission products. For example, an estimated 77% of the 10.4-megaton yield of the Ivy Mike thermonuclear test in 1952 came from fast fission of the depleted uranium tamper. Because depleted (or natural) uranium has no critical mass, it can be added to thermonuclear bombs in almost unlimited quantity. The Soviet Union's test of the Tsar Bomba in 1961 produced "only" 50 megatons of explosive power, over 90% of which came from fusion because the 238U final stage had been replaced with lead. Had 238U been used instead, the yield of the Tsar Bomba could have been well above 100 megatons, and it would have produced nuclear fallout equivalent to one third of the global total that had been produced up to that time.
Sources: en.wikipedia.org
On 18 January, ambassadors from all 27 member states of the EU held an emergency meeting on Trump's threats. After Trump reversed his decision on implementing tariffs, EU officials were sceptical, but announced on 22 January that approval of the trade agreement would resume.
=== Heart disease === Macrophages are the predominant cells involved in creating the progressive plaque lesions of atherosclerosis. Focal recruitment of macrophages occurs after the onset of acute myocardial infarction. These macrophages function to remove debris, apoptotic cells and to prepare for tissue regeneration.
=== Pharmacokinetics === A 2007 human pharmacokinetic study of sodium RLA demonstrated the maximum concentration in plasma and bioavailability are significantly greater than the free acid form, and rivals plasma levels achieved by intravenous administration of the free acid form. Additionally, high plasma levels comparable to those in animal models where Nrf2 was activated were achieved. The various forms of LA are not bioequivalent. Very few studies compare individual enantiomers with racemic lipoic acid. It is unclear if twice as much racemic lipoic acid can replace RLA. The toxic dose of LA in cats is much lower than that in humans or dogs and produces hepatocellular toxicity.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.